According to Xencor's latest financial reports the company's current earnings (TTM) are -$0.13 B. In 2022 the company made an earning of -$54.51 M a decrease over its 2021 earnings that were of $82.63 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.13 B | 120.95% |
2022 | -$54.51 M | -165.97% |
2021 | $82.63 M | -219.18% |
2020 | -$69.34 M | -355.02% |
2019 | $27.18 M | -138.61% |
2018 | -$70.42 M | 21.07% |
2017 | -$58.16 M | -336.25% |
2016 | $24.61 M | -239.93% |
2015 | -$17.6 M | 7.12% |
2014 | -$16.43 M | -72.75% |
2013 | -$60.26 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $16.97 B | -14,191.78% | ๐บ๐ธ USA |
AbbVie ABBV | $6.25 B | -5,289.35% | ๐บ๐ธ USA |
Amgen AMGN | $7.85 B | -6,621.97% | ๐บ๐ธ USA |
Merck MRK | $3.03 B | -2,619.95% | ๐บ๐ธ USA |
Seagen
SGEN | -$0.8 B | 556.41% | ๐บ๐ธ USA |
MacroGenics MGNX | -$9.06 M | -92.48% | ๐บ๐ธ USA |